Vikas Pai

A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

Rajendrakumar H. Jani, Vikas Pai, Pramod Jha et al. · Diabetes Technology & Therapeutics · 2013 · 110 citations · Full text

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)

Vikas Pai, A Paneerselvam, Satinath Mukhopadhyay et al. · Journal of Diabetes Science and Technology · 2014 · 108 citations · Full text

Comparative clinical trial of S-pantoprazole<i>versus</i>racemic pantoprazole in the treatment of gastro-esophageal reflux disease

Vikas Pai · World Journal of Gastroenterology · 2006 · 34 citations · Full text

Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia

Anil Pareek, Nitin Chandurkar, N K Thulaseedharan et al. · Current Medical Research and Opinion · 2015 · 34 citations

Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease

Vikas Pai · World Journal of Gastroenterology · 2007 · 30 citations · Full text